- Home
- DARE vs DYAI Comparison
DARE vs DYAI Comparison
Compare DARE & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- DYAI
- Stock Information
- Founded
- DARE 2015
- DYAI 1979
- Country
- DARE United States
- DYAI United States
- Employees
- DARE N/A
- DYAI N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DARE Health Care
- DYAI Health Care
- Exchange
- DARE Nasdaq
- DYAI Nasdaq
- Market Cap
- DARE 26.3M
- DYAI 28.3M
- IPO Year
- DARE N/A
- DYAI 2004
- Fundamental
- Price
- DARE $2.55
- DYAI $0.99
- Analyst Decision
- DARE Strong Buy
- DYAI Strong Buy
- Analyst Count
- DARE 3
- DYAI 1
- Target Price
- DARE $12.50
- DYAI $6.00
- AVG Volume (30 Days)
- DARE 4.3M
- DYAI 62.0K
- Earning Date
- DARE 08-11-2025
- DYAI 08-12-2025
- Dividend Yield
- DARE N/A
- DYAI N/A
- EPS Growth
- DARE N/A
- DYAI N/A
- EPS
- DARE N/A
- DYAI N/A
- Revenue
- DARE $25,909.00
- DYAI $3,554,344.00
- Revenue This Year
- DARE $74,787.57
- DYAI $22.56
- Revenue Next Year
- DARE $141.76
- DYAI $30.95
- P/E Ratio
- DARE N/A
- DYAI N/A
- Revenue Growth
- DARE N/A
- DYAI 57.59
- 52 Week Low
- DARE $2.11
- DYAI $0.91
- 52 Week High
- DARE $9.19
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- DARE 44.40
- DYAI 46.85
- Support Level
- DARE $2.11
- DYAI $0.91
- Resistance Level
- DARE $9.19
- DYAI $1.02
- Average True Range (ATR)
- DARE 0.60
- DYAI 0.05
- MACD
- DARE 0.03
- DYAI 0.01
- Stochastic Oscillator
- DARE 5.52
- DYAI 35.07
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.